Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2021-03-12 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES
Regulatory Filings Classification · 95% confidence The document is an announcement from Overseas Chinese Town (Asia) Holdings Limited regarding a waiver from strict compliance with a specific listing rule (Rule 14.41(a)) related to the timing of dispatching a circular to shareholders. It references a previous announcement and the upcoming circular but does not contain financial statements or detailed financial data. The document is short (2558 characters) and primarily serves as a regulatory announcement about procedural compliance and timing, not a full report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-12 English
POSSIBLE VERY SUBSTANTIAL DISPOSAL IN RELATION TO POSSIBLE FURTHER DISPOSAL OF LISTED SECURITIES IN TONGCHENG-ELONG
Capital/Financing Update Classification · 95% confidence The document is an announcement from Overseas Chinese Town (Asia) Holdings Limited regarding a possible very substantial disposal of listed securities in Tongcheng-Elong. It discusses seeking shareholder approval at an Extraordinary General Meeting (EGM) for a Disposal Mandate to dispose of shares on-market. The announcement includes detailed terms of the disposal, financial effects, reasons and benefits, and references to Listing Rules compliance. It is not a full financial report but a regulatory announcement about a significant transaction requiring shareholder approval. The document is lengthy (15,000 characters) and contains detailed transaction information but is not a financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes, specifically a disposal of a substantial equity investment. Therefore, the appropriate classification is CAP with high confidence.
2021-03-11 English
INSIDE INFORMATION ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED CONDITIONAL MARKETING APPROVAL FOR TELITACICEPT TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN CHINA
Regulatory Filings Classification · 95% confidence The document is an announcement by RemeGen Co., Ltd. regarding the conditional marketing approval granted by the National Medical Products Administration for their drug telitacicept to treat Systemic Lupus Erythematosus (SLE) in China. It is labeled as an "Inside Information Announcement" and references compliance with the Listing Rules and Inside Information Provisions. The content focuses on regulatory approval news and business development rather than financial results, management changes, or shareholder votes. The document is relatively short (4435 characters) and serves as a regulatory announcement of significant company news. It does not contain financial statements, earnings data, or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-03-11 English
Notification Letter and Request Form to Non-Registered Holders - Notice of Publication of Extraordinary General Meeting Circular ("Current Corporate Communications")
Report Publication Announcement Classification · 95% confidence The document is a notification letter to non-registered shareholders about the publication of an Extraordinary General Meeting (EGM) circular. It provides information on how to access the circular electronically and how to request printed versions. The document includes a request form for shareholders to choose their preferred format for receiving corporate communications. There is no substantive financial data, financial statements, or detailed report content included. The document is essentially an announcement about the availability of a corporate communication (the EGM circular) rather than the circular itself or any financial report. Therefore, it fits the category of Report Publication Announcement (RPA).
2021-03-04 English
PROXY FORM FOR USE AT THE 2021 FIRST EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a proxy form for the 2021 first extraordinary general meeting of RemeGen Co., Ltd. It includes instructions for shareholders to appoint proxies to vote on resolutions at the meeting. The content is focused on voting procedures and proxy appointments rather than the meeting materials or results themselves. This type of document is typically classified as Proxy Solicitation & Information Statement (PSI), as it is sent to shareholders to provide information and request votes for the meeting.
2021-03-04 English
NOTICE OF 2021 FIRST EXTRAORDINARY GENERAL MEETING
AGM Information Classification · 95% confidence The document is a notice for the 2021 First Extraordinary General Meeting (EGM) of RemeGen Co., Ltd. It includes details about the meeting date, location, agenda (special resolutions), proxy instructions, and shareholder voting rights. There are no financial statements, management discussion, or detailed financial data presented. The document serves as an announcement to shareholders about the upcoming EGM rather than a report or results of the meeting. Therefore, it fits the category of a meeting notice, which aligns with the AGM Information category (AGM-R) as it is related to a general meeting and provides materials for shareholders to prepare for the meeting.
2021-03-04 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.